Amy M. Scurlock
Professor
Faculty Researcher
Peds Pediatrics, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Amy M. Scurlock is a Professor of Pediatrics at the University of Arkansas for Medical Sciences (UAMS) and Arkansas Children’s Hospital (ACH) and Research Institute. Her clinical work involves caring for patients with a range of allergic and immunologic conditions, with specific interests in food allergy and primary immunodeficiency. She emphasizes patient- and family-centered care, integrating evidence-based management with consideration for social determinants of health.
Dr. Scurlock's research focuses on clinical trials in food allergy and eosinophilic gastrointestinal disorders, supported by federal, foundation, and industry funding. She is actively involved in the Food Allergy Research and Education (FARE) Clinical Network and FARE Neighborhoods Program, and serves as a Steering Committee member for the NIAID Consortium of Food Allergy Research (CoFAR). Her research interests also extend to evaluating mucosal immune responses in models of food allergy and eosinophilic gastrointestinal disorders. She has authored or co-authored 158 publications and has an h-index of 35, with 6,953 citations. Her work is recognized as high-impact, evidenced by her highly cited status.
Research Overview
Amy M. Scurlock, M.D. is an Associate Professor of Pediatrics at the University of Arkansas for Medical Sciences and Arkansas Children's Hospital. Dr. Scurlock is also a researcher at Arkansas Children's Hospital Research Institute. Dr. Scurlock received her M.D. in 1998 from the University of Arkansas for Medical Sciences. She completed a residency in Pediatrics at UAMS/ACH in 2001 and served as Chief Resident until 2002. She completed her Allergy-Immunology Fellowship Training at Duke University Medical Center in Durham North Carolina in 2004. Dr. Scurlock joined the UAMS faculty in August 2004 as a member of the Division of Pediatric Allergy/Immunology within the Department of Pediatrics. Dr. Scurlock's clinical interests include allergic and immunologic diseases such as food allergy, atopic dermatitis, eosinophilic esophagitis and primary immunodeficiency. She also has interest in newborn screening and long-term follow-up for infants with SCID and T-cell lymphopenia. Her research interests are focused on evaluation of mucosal immune responses in models of food allergy and eosinophilic gastrointestinal disorders. Dr. Scurlock is a member of the American Academy of Allergy Asthma and Immunology (AAAAI), Society for Mucosal Immunology, Society for Pediatric Research, Clinical Immunology Society, and American Academy of Pediatrics. She is board certified in both Pediatrics and Allergy-Immunology. Some of the UAMS College of Medicine faculty members provide pediatric patient care at Arkansas Children's Hospital. In addition, a wide range of pediatric services are provided in more than 35 subspecialties around Arkansas in locations such as the Schmieding Developmental Center in Springdale and the James L. Dennis Developmental Center in Little Rock. To make an appointment at Arkansas Children's Hospital, please call 501-364-4000.
Metrics
- h-index: 35
- Publications: 158
- Citations: 7,026
Selected Publications
-
Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy (2026)
-
Early-life peanut oral immunotherapy associated with long-term ingestion and immunologic changes (2026)
-
Implementation of early peanut introduction among providers in a southern US state (2026)
-
Management of Gastrointestinal Symptoms During Oral Immunotherapy: Guidance from OUtMATCH Investigators (2026)
-
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies (2025)
-
Introduction of allergenic foods after treatment with omalizumab (2025)
-
Introduction Of Allergenic Foods After Treatment With Omalizumab (2025)
-
Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes (2025)
-
Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent (2024)
-
Food Insecurity and Health Inequities in Food Allergy (2024)
-
Long-term walnut oral immunotherapy induces shifts in serum antibody binding patterns to walnut and cross-reactive tree nuts (2024)
-
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial (2024)
-
Survey of Arkansas Pediatric Providers on the Application of the NIH/NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States (2024)
-
Food insecurity and allergic diseases: A call to collective action (2023)
-
Peanut allergy (2023)
Grants & Funding
As listed on this researcher's institutional profile.
- FARE Network UAMS ACHRI Flow Through Principal Investigator
- Immunoregulatory Networks in Chlamydia Genital Tract Infection NIH Principal Investigator
Collaboration Network
Top Collaborators
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy
- Food insecurity and allergic diseases: A call to collective action
- Introduction of allergenic foods after treatment with omalizumab
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
Showing 5 of 9 shared publications
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Introduction of allergenic foods after treatment with omalizumab
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
- Introduction Of Allergenic Foods After Treatment With Omalizumab
Showing 5 of 6 shared publications
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- The SunBEAm birth cohort: Protocol design
- Introduction of allergenic foods after treatment with omalizumab
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
- Introduction of allergenic foods after treatment with omalizumab
- Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy
- Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy
- Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
- Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- The SunBEAm birth cohort: Protocol design
- Food insecurity and allergic diseases: A call to collective action
- Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Introduction of allergenic foods after treatment with omalizumab
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- The SunBEAm birth cohort: Protocol design
- Introduction of allergenic foods after treatment with omalizumab
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes
- Survey of Arkansas Pediatric Providers on the Application of the NIH/NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States
- Long-term walnut oral immunotherapy induces shifts in serum antibody binding patterns to walnut and cross-reactive tree nuts
- Implementation of early peanut introduction among providers in a southern US state
- Introduction of allergenic foods after treatment with omalizumab
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- Introduction of allergenic foods after treatment with omalizumab
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
- Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy
- Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
- Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Introduction of allergenic foods after treatment with omalizumab
- Introduction Of Allergenic Foods After Treatment With Omalizumab
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
Similar Researchers
Based on overlapping research topics